PortfoliosLab logo
Beam Therapeutics Inc. (BEAM)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US07373V1052

CUSIP

07373V105

IPO Date

Feb 6, 2020

Highlights

Market Cap

$2.20B

EPS (TTM)

-$1.58

Total Revenue (TTM)

$349.64M

Gross Profit (TTM)

$327.80M

EBITDA (TTM)

-$160.83M

Year Range

$20.84 - $49.50

Target Price

$49.20

Short %

16.86%

Short Ratio

8.86

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Beam Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember
5.62%
6.22%
BEAM (Beam Therapeutics Inc.)
Benchmark (^GSPC)

Returns By Period

Beam Therapeutics Inc. had a return of 0.00% year-to-date (YTD) and -8.89% in the last 12 months.


BEAM

YTD

0.00%

1M

-9.39%

6M

9.88%

1Y

-8.89%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.00%

1M

-2.50%

6M

6.76%

1Y

23.31%

5Y*

12.57%

10Y*

11.09%

*Annualized

Monthly Returns

The table below presents the monthly returns of BEAM, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-10.36%61.84%-16.33%-35.77%12.25%-1.64%35.04%-15.68%-8.17%-10.57%24.92%-8.89%
202311.10%-7.39%-23.91%0.29%3.87%0.09%-3.32%-24.91%3.75%-12.10%32.83%-3.06%-30.40%
2022-13.15%13.21%-26.87%-34.50%-6.26%10.03%62.70%-13.31%-12.75%-7.51%4.83%-15.33%-50.92%
202118.12%-7.57%-10.20%2.45%-4.60%64.53%-28.52%20.57%-21.56%2.02%-10.84%0.68%-2.39%
202019.95%-19.96%-11.39%60.19%9.59%-30.93%29.83%-1.95%38.79%46.33%63.28%335.41%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BEAM is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BEAM is 4444
Overall Rank
The Sharpe Ratio Rank of BEAM is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of BEAM is 4646
Sortino Ratio Rank
The Omega Ratio Rank of BEAM is 4444
Omega Ratio Rank
The Calmar Ratio Rank of BEAM is 4343
Calmar Ratio Rank
The Martin Ratio Rank of BEAM is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for BEAM, currently valued at -0.12, compared to the broader market-4.00-2.000.002.00-0.121.84
The chart of Sortino ratio for BEAM, currently valued at 0.37, compared to the broader market-4.00-2.000.002.004.000.372.48
The chart of Omega ratio for BEAM, currently valued at 1.04, compared to the broader market0.501.001.502.001.041.34
The chart of Calmar ratio for BEAM, currently valued at -0.11, compared to the broader market0.002.004.006.00-0.112.75
The chart of Martin ratio for BEAM, currently valued at -0.23, compared to the broader market0.005.0010.0015.0020.0025.00-0.2311.85
BEAM
^GSPC

The current Beam Therapeutics Inc. Sharpe ratio is -0.12. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Beam Therapeutics Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00AugustSeptemberOctoberNovemberDecember
-0.12
1.84
BEAM (Beam Therapeutics Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Beam Therapeutics Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember
-81.44%
-3.43%
BEAM (Beam Therapeutics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Beam Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Beam Therapeutics Inc. was 86.76%, occurring on Oct 20, 2023. The portfolio has not yet recovered.

The current Beam Therapeutics Inc. drawdown is 81.44%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-86.76%Jul 2, 2021580Oct 20, 2023
-54.42%Feb 14, 202021Mar 16, 202077Jul 6, 202098
-46.9%Feb 9, 202163May 10, 202136Jun 30, 202199
-37.83%Jul 10, 202017Aug 3, 202052Oct 15, 202069
-20.59%Jan 19, 20216Jan 26, 20218Feb 5, 202114

Volatility

Volatility Chart

The current Beam Therapeutics Inc. volatility is 22.08%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember
22.08%
4.15%
BEAM (Beam Therapeutics Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Beam Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Beam Therapeutics Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items